Related Experiment Video
Updated: Aug 10, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
[Ketotifen in allergic diseases]
1Servicio de Alergia, Instituto Nacional de Pediatría.
Abstract:
This study included the review of 1000 clinical histories of allergic diseases, in a retrospective way, that was seeing in the Service of Allergy of the Instituto Nacional de Pediatría in Mexico city. All the patients were previously diagnosed with several allergic pathologiest like: bronchial asthma, rhinitis, asthma and rhinitis, atopic dermatitis, etc. All the patients received as main therapeutic treatment ketotifen at least during 3 months to 12 months. Global improvement in all patients with the use of ketotifen, reach 84%, including all the pathologiest studied. The tolerance of the drug specially in children was very good.
Related Concept Videos
Allergic Drug Reactions
Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

